Kaitlyn Bader, Assistant Managing Editor

Catch up on coverage from the third day of the 2026 American Academy of Dermatology Annual Meeting held in Denver, Colorado.

At AAD 2026, Christopher Bunick, MD, PhD, and Reid Waldman, MD, discuss investigational VDPHL01, extended-release oral minoxidil, for the treatment of women and men with pattern hair loss.

At AAD 2026, Helen He, MD, highlights how minimally invasive molecular profiling distinguishes photoexposed and photoprotected aging trajectories.

Catch up on coverage from the second day of the 2026 American Academy of Dermatology Annual Meeting held in Denver, Colorado.

At AAD 2026, Melinda Gooderham, MSc, MD, FRCPC, reviewed late-breaking zasocitinib data for psoriasis, noting that 70% of patients reached sPGA 0/1.

Christopher Bunick, MD, PhD, and Kristian Reich, MD, PhD, discuss the long-term efficacy of sonelokimab, with more than 60% of patients achieving HiSCR75 and approximately 30% reaching HiSCR100.

At AAD 2026, Christopher Bunick, MD, PhD, and Patrick Burnett, MD, PhD, discuss late-breaking data of roflumilast cream's improvements in infants with AD.

Catch up on coverage from the first day of the 2026 American Academy of Dermatology Annual Meeting held in Denver, Colorado.

Nicole Negbenebor, MD, highlights the clinical and professional impact of community-driven education and evidence-based focus in skin of color dermatology.

Christopher Bunick, MD, PhD, interviews medical student Sabine Obagi on the value of conference participation, mentorship, and early exposure for aspiring dermatology clinicians at AAD 2026.

Read more on how to navigate all the opportunities at this year’s AAD meeting, which starts today in Denver, Colorado.

At the pre-AAD meeting, Regina Benjamin, MD, MBA, discussed the role of clinicians as leaders in addressing social determinants of health, emphasizing prevention, education, and culturally responsive care.

Susan C. Taylor, MD, moderated a recent Case-Based Roundtable discussion on topical treatment options for vitiligo.

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, reviewed clinical trial and long-term data supporting biologic therapies for HS, emphasizing individualized patient selection and timing of intervention.

Mark Lebwohl, MD, reviews how the AdvanceAD-Tx 487-GEP test identifies which patients are likely to need a JAK inhibitor rather than a biologic.

Douglas DiRuggiero, DMSc, MHS, PA-C, reviewed clinical cases highlighting the distinct roles of topical ruxolitinib, tapinarof, and roflumilast in managing itch, inflammation, and long-term disease control in atopic dermatitis.

Mark Lebwohl, MD, discusses how the 487-GEP test may help clinicians identify the most appropriate systemic therapy for patients with AD earlier in the treatment journey.

Dylan Timmermann, PA-C, reflects on the experiences that shaped his career trajectory in dermatology and offers insights relevant to physician assistants and nurse practitioners entering the specialty.

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, highlighted that CHE is often mischaracterized and frequently involves overlapping subtypes.

Omar Noor, MD, shares pearls on type 2 inflammation, including dupilumab insights for atopic dermatitis, prurigo nodularis, and CSU at Horizons in Advanced Practice.

Priovant Therapeutics' brepocitinib has been assigned a Prescription Drug User Fee Act date in the third quarter of 2026.

After TMB-001 did not meet its primary end point in the ASCEND trial, LEO Pharma moved to out-license the vehicle formulation, which unexpectedly provided a response in 40% of patients.

In a recent Expert Perspectives video series, Omar Noor, MD, discussed the complexity of chronic hand eczema and how a topical pan-JAK inhibitor can improve quality of life.

In the latest Cutaneous Connection podcast episode, Renata Block, DMSc, MMS, PA-C, and patient advocate Suki Tipp discuss the clinical, emotional, and financial toll of delayed diagnosis of indolent systemic mastocytosis.

Patient advocate Suki Tipp details her progression from misattributed cutaneous findings and fragmented specialty care to life-threatening anaphylaxis and eventual disease control with targeted therapy.

Castle Biosciences’ AdvanceAD-Tx test stratifies patients by molecular profile, identifying patients more likely to achieve faster and deeper responses with JAKs compared with Th2-targeted treatments.

Around 800 rare skin diseases affect 6.8 million people worldwide, including epidermolysis bullosa, generalized pustular psoriasis, ichthyosis, and erythropoietic protoporphyria.

Todd Schlesinger, MD, highlights data supporting red light–activated PDT with 10% ALA gel for superficial basal cell carcinoma, discussing structured treatment protocols and manageable tolerability.

Todd Schlesinger, MD, reviews emerging randomized trial data supporting red light–activated photodynamic therapy with 10% aminolevulinic acid gel and outlines key considerations for patient selection in superficial basal cell carcinoma (sBCC).

Todd Schlesinger, MD, discusses emerging evidence, clearance outcomes, and practical considerations for using red light–based photodynamic therapy as a nonsurgical option in select superficial basal cell carcinoma (BCC) cases.